These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35849876)

  • 1. Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract.
    Kim DY; Kwon YJ; Seo WY; Kim UI; Ahn S; Choi SM; Bang HT; Kim K; Kim JS
    Eur J Cancer; 2022 Sep; 173():41-51. PubMed ID: 35849876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.
    Chen M; Mashima T; Oishi T; Muramatsu Y; Seto Y; Takamatsu M; Kawata N; Morino S; Nakamura A; Inaba S; Yuan X; Maruyama K; Suzuki M; Sato A; Yoshida H; Jang MK; Mizutani A; Takeuchi K; Yamaguchi K; Shirai F; Nagayama S; Katayama R; Seimiya H
    Br J Cancer; 2024 Jan; 130(1):151-162. PubMed ID: 37968472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
    Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
    Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
    Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
    Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer.
    Morino S; Mashima T; Shirai F; Nagayama S; Katayama R; Seimiya H
    Cancer Lett; 2024 Mar; 584():216632. PubMed ID: 38216082
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
    Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.
    Schatoff EM; Goswami S; Zafra MP; Foronda M; Shusterman M; Leach BI; Katti A; Diaz BJ; Dow LE
    Cancer Discov; 2019 Oct; 9(10):1358-1371. PubMed ID: 31337618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy.
    Siraj AK; Kumar Parvathareddy S; Pratheeshkumar P; Padmaja Divya S; Ahmed SO; Melosantos R; Begum R; Concepcion RMJA; Al-Sanea N; Ashari LH; Abduljabbar A; Al-Dayel F; Al-Kuraya KS
    Biomed Pharmacother; 2020 Jan; 121():109572. PubMed ID: 31704613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
    Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H
    Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
    Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
    McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
    Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of tankyrase and peroxiredoxin II is indispensable for the survival of colorectal cancer cells.
    Kang DH; Lee DJ; Lee S; Lee SY; Jun Y; Kim Y; Kim Y; Lee JS; Lee DK; Lee S; Jho EH; Yu DY; Kang SW
    Nat Commun; 2017 Jun; 8(1):40. PubMed ID: 28659575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.
    Croy HE; Fuller CN; Giannotti J; Robinson P; Foley AVA; Yamulla RJ; Cosgriff S; Greaves BD; von Kleeck RA; An HH; Powers CM; Tran JK; Tocker AM; Jacob KD; Davis BK; Roberts DM
    J Biol Chem; 2016 Jun; 291(24):12747-12760. PubMed ID: 27068743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
    Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
    Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
    Mariotti L; Pollock K; Guettler S
    Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Novel Triazolopyridine Derivative as a Tankyrase Inhibitor.
    Ryu H; Nam KY; Kim HJ; Song JY; Hwang SG; Kim JS; Kim J; Ahn J
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
    Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
    Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.